Rohto Pharmaceutical Raises Dividend and Signals Further Payout Growth

Rohto Pharmaceutical Co ( (JP:4527) ) just unveiled an update.

Rohto Pharmaceutical’s board has approved a year-end dividend of 25 yen per share for the fiscal year ended March 31, 2026, with total payouts of 5,649 million yen from retained earnings and an effective date of June 8, 2026. This raises the annual dividend to 46 yen per share, up from 36 yen in the previous fiscal year, and the company is forecasting a further increase to a total of 50 yen per share in the year ending March 31, 2027, underscoring a continued commitment to enhancing shareholder returns.

The higher year-end dividend and planned further uplift signal confidence in Rohto Pharmaceutical’s earnings strength and cash flow capacity, positioning the company as a steadily growing income stock within the Japanese healthcare sector. For investors, the step-up in dividends suggests management’s willingness to share profits more generously while maintaining financial discipline, potentially improving the stock’s appeal to income-focused and long-term shareholders.

The most recent analyst rating on (JP:4527) stock is a Buy with a Yen2980.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.

More about Rohto Pharmaceutical Co

Rohto Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company listed on the TSE Prime that develops and sells over-the-counter medicines, skincare products and related healthcare items. The company focuses on consumer health and wellness markets, leveraging its retained earnings and stable cash generation to support shareholder returns through regular dividends.

Average Trading Volume: 822,721

Technical Sentiment Signal: Buy

Current Market Cap: Yen591B

For a thorough assessment of 4527 stock, go to TipRanks’ Stock Analysis page.